



Northern/Western Europe: Belgium, Denmark, France, Germany, Italy, Netherlands, Portugal, Spain, Sweden, United Kingdom. Central/Eastern Europe: Austria, Czech Republic, Greece, Hungary, Poland, Romania, Russia, Turkey.
MEM-NS, meropenem non-susceptible (MIC > 2 mg/L) by EUCAST 2018 guidelines.

Conclusions: There were substantial differences in the distribution and incidence of carbapenemase types within Europe. Though the ATLAS surveillance program is not structured to measure the prevalence of resistance mechanisms, the general distribution of carbapenemase types and countries in which the highest percentages of CPE were observed were consistent with published reports.

